EXPRESSION PATHOLOGY, INC.
Patent Owner
Stats
- 28 US PATENTS IN FORCE
- 3 US APPLICATIONS PENDING
- Jan 16, 2018 most recent publication
Details
- 28 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 232 Total Citation Count
- Mar 10, 2004 Earliest Filing
- 7 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
Publication #
Title
Filing Date
Pub Date
Intl Class
2017/0248,608 Epidermal Growth Factor Receptor (EGFR) Protein SRM AssayFeb 27, 17Aug 31, 17[A61K, G01N, C07K]
2016/0334,424 SRM/MRM Assay for the Fibroblast Growth Factor Receptor 2 (FGFR2) proteinMay 16, 16Nov 17, 16[G01N]
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
9804164 SRM/MRM assay for the fatty acid synthase proteinApr 11, 16Oct 31, 17[A61K, C12Q, G01N, C07K]
9746477 Quantifying FR-α and GART proteins for optimal cancer therapyAug 01, 16Aug 29, 17[A61K, G01N]
9733253 Secreted protein acidic and rich in cysteine (SPARC) protein SRM assayJun 21, 12Aug 15, 17[A61K, G01N, C07K]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2013/0079,425 Urokinase-Type Plasminogen Activator Protein /Plasminogen Activator Inhibitor Type-1 Protein Selected Reaction Monitoring AssayAbandonedNov 26, 12Mar 28, 13[C12Q]
2013/0011,408 Epidermal Growth Factor Receptor (EGFR) Protein SRM AssayAbandonedJun 21, 12Jan 10, 13[A61K, G01N]
2011/0105,337 METHOD OF DISCOVERING AND ANALYZING SECRETED BIOMARKERS OF DISEASE FROM SOLID TISSUEAbandonedJun 23, 08May 05, 11[C12Q, C40B]
2011/0028,344 BIOMARKERS FOR ENDOMETRIAL DISEASEAbandonedApr 13, 09Feb 03, 11[C12Q, G01N, C40B, C07K]
2009/0263,842 METHOD OF ASSESSING THE METASTATIC STATUS OF A PRIMARY TUMORAbandonedMar 26, 07Oct 22, 09[C12Q]
Top Inventors for This Owner
Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.